Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Batimastat-coated stent enters pivotal trial:

This article was originally published in Clinica

Executive Summary

Biocompatibles International and British Biotech have begun a pivotal European clinical trial of a batimastat-coated coronary stent, which the firms are developing jointly. The BRILLIANT II trial, a 400-patient, multicentre, double-blind, randomised study, is evaluating Biocompatibles' BiodivYsio stent coated with British Biotech's drug as a means of reducing restenosis in patients who have undergone angioplasty. Data from the trial will be used to support a European marking application. The two companies this month announced a joint US trial of the drug-coated stent (see Clinica No 990, p 17).





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts